Seven Fleet Capital Management LP Takes Position in Compass Pathways PLC Sponsored ADR $CMPS

Seven Fleet Capital Management LP purchased a new position in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) during the 4th quarter, Holdings Channel.com reports. The firm purchased 40,000 shares of the company’s stock, valued at approximately $276,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Royal Bank of Canada increased its position in Compass Pathways by 49.8% during the 1st quarter. Royal Bank of Canada now owns 89,446 shares of the company’s stock valued at $256,000 after buying an additional 29,733 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Compass Pathways by 42.0% in the first quarter. Acadian Asset Management LLC now owns 240,591 shares of the company’s stock worth $686,000 after acquiring an additional 71,112 shares in the last quarter. Nantahala Capital Management LLC grew its stake in shares of Compass Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after acquiring an additional 1,350,698 shares during the last quarter. Balyasny Asset Management L.P. increased its holdings in shares of Compass Pathways by 38.0% during the second quarter. Balyasny Asset Management L.P. now owns 854,840 shares of the company’s stock valued at $2,394,000 after acquiring an additional 235,345 shares in the last quarter. Finally, Northeast Financial Consultants Inc bought a new position in shares of Compass Pathways during the second quarter valued at $59,000. Institutional investors own 46.19% of the company’s stock.

Compass Pathways Stock Performance

Shares of CMPS opened at $12.53 on Friday. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -3.98 and a beta of 2.50. The business’s fifty day simple moving average is $10.09 and its two-hundred day simple moving average is $7.81. Compass Pathways PLC Sponsored ADR has a 12 month low of $2.25 and a 12 month high of $14.76. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.15. Research analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Jefferies Financial Group raised Compass Pathways to a “strong-buy” rating in a research report on Tuesday, May 5th. Royal Bank Of Canada raised their price objective on shares of Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. UBS Group set a $18.00 target price on shares of Compass Pathways in a report on Thursday, May 7th. Maxim Group lifted their target price on shares of Compass Pathways from $12.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, May 15th. Finally, Wall Street Zen upgraded shares of Compass Pathways from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.36.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.